Failed Anxiety Drug May Fight Cancer
Posted on: Saturday, 6 September 2008, 03:00 CDT
An unsuccessful anxiety drug may open a novel gateway for the treatment of cancer, Scandinavian researchers suggest.
Siramesine -- a drug molecule developed by Lundbeck A/S to treat anxiety but discontinued due to unsatisfying trials -- was first shown to inhibit the growth of cultured cancer cells as well as that of solid tumors in mice by Danish scientists.
Researchers at the University of Helsinki, led by Paavo Kinnunen, are studying how the drug may promote apoptosis -- programmed cell death by which organisms deal with defective cells. Cancer cells survive by avoiding apoptosis.
The researchers find the production of phosphatidic acid acts as a signaling molecule for cells promoting cellular growth which can help prevent apoptosis. Siramesine may slow production of phosphatidic acid and so promote apotosis.
"The key finding of our study was that siramesine avidly and specifically binds to phosphatidic acid," Dr. Mikko Parry of University of Helsinki says in a statement. "Importantly, this is the first time it's shown that a lipid second messenger can act as a drug target: It is a totally new mechanism of action and constitutes a novel paradigm for developing new, more effective anti-cancer drugs."
Source: United Press International
Related Articles
- Helicos Announces Order for a Helicos Genetic Analysis System From a Leading U.S. Cancer Center for Cancer Stem Cell Research
- Canada Joins California in Cancer Stem Cell Research, Donates $100 Million
- Minister Clement, Governor Schwarzenegger Join Forces to Fight Cancer Through Cancer Stem Cell Research
- Stanford Researchers Create Cancer Stem Cells
- New Report Examines Emerging Therapeutic, Diagnostic and Market Opportunities in the Area of Cancer Stem Cell Research
- Cancerous Stem Cells Researched
- Stanford Gets $20M Cancer-Stem Cell Site
- $20 Million Gift to Establish Cancer Stem Cell Research Center at Stanford
- Emphasis on Cancer Stem Cell Research at Stanford Grows With Recruitment of Second Top Scientist
- ProlX Pharmaceuticals Designated Corporate Partner in $5.6 Million Grant to Fund Targeted Therapy Cancer Drug Discovery Research
User Comments (0)

RSS Feeds